Although some SOD1 drugs have been developed for clinics to treat a wide spectrum of human diseases, including Peyronie's disease [29], rheumatoid arthritis [30], and acute lung injury [31], without demonstrable toxicities [32], unfortunately, large-scale manufacturing and clinical use of hSOD1 are still limited because of the challenge of rapid and inexpensive production of high-quality hSOD1 in recombinant forms. This evidence concerns the gene SOD1 and rheumatoid arthritis.